Quanterix QTRX recently announced the submission of a 510(k) premarket notification to the FDA for its multi-analyte ...

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that the company’s PurISTSM algorithmic test has received a ...

Tempus AI (TEM) announced the clinical launch of its Immune Profile Score (IPS) algorithmic test. IPS, which is now available for clinicians to order, is a multimodal biomarker that can be used as a ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the clinical launch of its ...

IPS is a multimodal biomarker that combines known and novel clinical and immune-related biomarkers from DNA and RNA analysis to predict a patient's response to ICI-based therapy. The new clinical ...

Tempus AI has an immunology risk testing product ready for researchers to test out and is working with Cleveland Clinic on better ways to assess how immunotherapy might work on patients. The ...

Quanterix Corporation, announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration ...

Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced it has submitted a 510(k) premarket ...

The test integrates the measurements of five proteins to assess if patients have the brain pathology characteristic of Alzheimer's disease.